Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + tislelizumab
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fruquintinib + tislelizumab is an investigational combination therapy for cancer, particularly being studied in metastatic colorectal cancer and other solid tumors. Fruquintinib is a highly selective, potent oral small-molecule inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1/2/3), designed to block tumor angiogenesis and improve tolerability by minimizing off-target effects. Tislelizumab is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), engineered to minimize Fcγ receptor binding on macrophages and reduce T-cell clearance. The combination aims to leverage antiangiogenic effects with immune checkpoint inhibition for synergistic antitumor activity[5][6][8].
- Brand names
- Fruzaqla
- Other names
- Fruquintinib plus Tislelizumab
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on fruquintinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + tislelizumab.